What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “ZE66-0205 oral soft gelatin capsules, 50 mg strength. Participants will receive the assigned total dose orally with approximately 240 mL of water. Planned nominal single-dose levels are 50 mg, 100 mg, 200 mg, and 300 mg. If twice-daily dosing is evaluated, a second dose will be administered approximately 12 hours after the morning dose.”In the company’s words, NCT07735728 on ClinicalTrials.gov
- Main trialPhase 1
- “This first-in-human study will evaluate ZE66-0205 in healthy adults. The main purpose is to assess the safety and tolerability of single oral doses and, if evaluated, two doses given on Day 1. The study will also assess how ZE66-0205 is absorbed, distributed, and eliminated from the body and how it affects MALT1 levels in blood cells. Participants will be assigned by chance to receive ZE66-0205 or placebo in sequential ascending-dose cohorts.”In the company’s words, NCT07735728 on ClinicalTrials.gov
Coming up1
- 15 Aug 2027Phase 1 trial completes · ClinicalTrials.gov
Changes1
Last 90 days- 9 NovStatus changed: Not yet recruiting to Recruiting · ClinicalTrials.gov NCT07735728
Trials1
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 1Recruiting | 15 Aug 2027 | A First-in-Human Study of ZE66-0205 in Healthy Volunteers |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026